Dayong Gu

Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Salvage involved-field versus extended-field chemoradiotherapy for postoperative lymph node metastasis in esophageal squamous cell carcinoma: a retrospective clinical study.

Salvage involved-field versus extended-field chemoradiotherapy for postoperative lymph node metastasis in esophageal squamous cell carcinoma: a retrospective clinical study.

Journal: BMC cancer

Published: May 18, 2025

A phase II study of anlotinib plus whole brain radiation therapy for patients with NSCLC with multiple brain metastases.

A phase II study of anlotinib plus whole brain radiation therapy for patients with NSCLC with multiple brain metastases.

Journal: Annals of medicine

Published: October 24, 2024

Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study.

Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study.

Journal: International immunopharmacology

Published: March 17, 2024

Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older.

Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older.

Journal: Radiation oncology (London, England)

Published: January 21, 2024

Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer.

Comparison of immunochemotherapy followed by surgery or chemoradiotherapy in locally advanced esophageal squamous cell cancer.

Journal: International immunopharmacology

Published: December 25, 2023

Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial.

Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial.

Journal: EClinicalMedicine

Published: September 26, 2023

Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report.

Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report.

Journal: Medicine

Published: August 06, 2023

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.

Journal: Frontiers in immunology

Published: August 29, 2022

Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.

Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.

Journal: Radiation oncology (London, England)

Published: April 20, 2022

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial.

Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial.

Journal: Frontiers in oncology

Published: March 20, 2022

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.

Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.

Journal: JAMA network open

Published: February 21, 2022

An Immune Cell-Based Signature Associating With EMT Phenotype Predicts Postoperative Overall Survival of ESCC.

An Immune Cell-Based Signature Associating With EMT Phenotype Predicts Postoperative Overall Survival of ESCC.

Journal: Frontiers in oncology

Published: December 01, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026